GlassScriptPhysician profile
Parker C Grow
NPI 1346335536
$5,124.91
in general payments reported to CMS, 2019-2025
22 companies · $939 in 2025
The $939 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $791 · 2021: $539 · 2022: $854 · 2023: $457 · 2024: $752 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,436.83 | 2019-2025 | Aveir, Confirm Rx, Gallant |
| Boston Scientific Corporation | $286.32 | 2023-2025 | Watchman Flx, Bodyguardian, Cds - Mct/Cem Monitoring |
| Novartis Pharmaceuticals Corporation | $274.04 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $221.82 | 2020-2025 | Lifevest |
| Amgen INC. | $154.77 | 2021-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $139.70 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $88.97 | 2021-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $83.91 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $67.60 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $63.25 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $61.92 | 2021 | |
| Irhythm Technologies, INC. | $43.74 | 2021 | |
| Chiesi USA, INC. | $31.93 | 2019-2024 | Kengreal |
| Sanofi-Aventis U.S. LLC | $28.63 | 2021-2022 | |
| Abiomed | $27.74 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $20.88 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $19.96 | 2025 | |
| Cardiovascular Systems INC. | $18.27 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.76 | 2022 | |
| Pfizer INC. | $14.34 | 2021 | |
| Medtronic Vascular, INC. | $13.02 | 2020 | |
| Alnylam Pharmaceuticals INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parker Grow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.